Hybrid open access journals

Presidio Medical Announces Appointment of New Chief Executive Officer

Retrieved on: 
Monday, June 28, 2021
General Health, Health, Clinical trials, Medical devices, Branches of biology, Neuroscience, California, Neurotechnology, Hybrid open access journals, Neuromodulation, Neurophysiology, Pain, Presidio of San Francisco

Presidio Medical, Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, today announced that Michael Onuscheck has been named the incoming Chief Executive Officer and Chairman of the Board.

Key Points: 
  • Presidio Medical, Inc., a clinical-stage medical device company developing a transformational neuromodulation platform, today announced that Michael Onuscheck has been named the incoming Chief Executive Officer and Chairman of the Board.
  • Michael Ackermann will continue to serve on the Board of Directors at Presidio and remain close with the company.
  • Michael Onuscheck is the Lebron James of neuromodulation and one of the worlds premier leaders in medical technology.
  • In April, Presidio also announced the executive appointment of Katherine Neuenfeldt, who previously was on the Executive Team at Nevro Corp. and led the highly successful launch of HF10 therapy.

Presidio Medical Announces New Executive Appointment

Retrieved on: 
Tuesday, April 20, 2021
Biotechnology, Medical devices, Health, Clinical trials, Managed care, Branches of biology, Neuroscience, Hybrid open access journals, Neuromodulation

b'Presidio Medical, Inc. , a clinical-stage medical device company developing a neuromodulation platform, today announced that Katherine H. Neuenfeldt has joined the Executive Team as Vice President, Marketing.\nMs.

Key Points: 
  • b'Presidio Medical, Inc. , a clinical-stage medical device company developing a neuromodulation platform, today announced that Katherine H. Neuenfeldt has joined the Executive Team as Vice President, Marketing.\nMs.
  • in Epidemiology from the Stanford School of Medicine, and a M.B.A. from the Darden School of Business at the University of Virginia.\n\xe2\x80\x9cWe are thrilled to welcome Katherine to our leadership team,\xe2\x80\x9d said Michael Ackermann, co-founder and Chief Executive Officer of Presidio Medical.
  • The company is also researching the application of its novel technology for additional indications across several therapeutic areas with significant unmet medical needs.
  • For more information about APVC visit www.actionpotentialvc.com .\nPresidio Medical was founded in 2017 and is headquartered in South San Francisco.

Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro's HF10® Therapy

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Neuroscience, Nervous system, Acute pain, Neurotechnology, North American Neuromodulation Society, Hybrid open access journals, Neuromodulation, Pain management, Nans, Opioid, Pain

Results were presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.

Key Points: 
  • Results were presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.
  • The data presented at NANS highlighted complete 6-month results and analysis of all prespecified secondary endpoints and a first look at 12-month pain relief and preliminary crossover results.
  • E-Poster presented at the North American Neuromodulation Society Meeting 2021 Orlando, FL.
  • HF10 therapy has demonstrated the ability to reduce or eliminate opioids in 65% of patients across six peer-reviewed clinical studies.

Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting

Retrieved on: 
Thursday, January 14, 2021
Software, Branches of biology, Operating systems, Neurotechnology, Hybrid open access journals, North American Neuromodulation Society, Real-time web, Text messaging, LinkedIn, Neuromodulation, La Senza, Instagram

Results will be presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.

Key Points: 
  • Results will be presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021.
  • "Nevro is proud to continue our longstanding commitment to investing in the field of neuromodulation and expanding our growing body of clinical evidence," said D. Keith Grossman, Chairman, CEO and President of Nevro.
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
  • Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
    To learn more about Nevro, connect with us on LinkedIn , Twitter , Facebook and Instagram .

ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device

Retrieved on: 
Thursday, September 10, 2020
Organ systems, Branches of biology, Clinical medicine, Neurotechnology, Hybrid open access journals, Diabetes management, Diabetes, Neuromodulation

SAN CLEMENTE, Calif., Sept. 10, 2020 /PRNewswire/ --ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation (DBSN) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints.

Key Points: 
  • SAN CLEMENTE, Calif., Sept. 10, 2020 /PRNewswire/ --ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation (DBSN) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints.
  • These findings broaden the proof-of-concept and mechanism of action, results of which were initially presented at ObesityWeek 2018.
  • Further demonstrating that dual vagus nerve neuromodulation a novel and proprietary approach - improves glycemic control in animal models of T2DM.
  • "The ReShape Lifesciences Diabetes Bloc-Stim Neuromodulation technology has accomplished key goals through the NIH Phase I Small Business Innovation Research grant study.

Worldwide Neuromodulation Devices Market to 2030 - COVID-19 Impact - ResearchAndMarkets.com

Retrieved on: 
Friday, August 7, 2020
Medical devices, Health, Neuroscience, Branches of biology, Organ systems, Hybrid open access journals, Demographics, Market segmentation, Neuromodulation, Market analysis

The "Neuromodulation Devices (Neurology Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices (Neurology Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on Neuromodulation Devices market for the year 2020 and beyond.
  • Annualized total Neuromodulation Devices market revenue by segment and market outlooks from 2015-2030.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Neuromodulation Devices market in the future.

Neuromodulation Market Worth $8.8 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, February 28, 2020
Branches of biology, Neuroscience, Organ systems, Neurotechnology, Neurophysiology, Hybrid open access journals, Neuromodulation, Neuropsychology, International Neuromodulation Society, North American Neuromodulation Society

The internal neuromodulation segment accounted for the largest share of the Neuromodulation Market.

Key Points: 
  • The internal neuromodulation segment accounted for the largest share of the Neuromodulation Market.
  • Based on technology, the neuromodulation is segmented into internal neuromodulation and external neuromodulation.
  • The internal neuromodulation segment accounted for the largest share of the market in 2019.
  • The transcutaneous electrical nerve stimulation segment accounted for the largest share of the External Neuromodulation Market in 2019.

Neuromodulation Market Worth $8.8 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, February 28, 2020
Branches of biology, Neuroscience, Organ systems, Neurotechnology, Neurophysiology, Hybrid open access journals, Neuromodulation, Neuropsychology, International Neuromodulation Society, North American Neuromodulation Society

The internal neuromodulation segment accounted for the largest share of the Neuromodulation Market.

Key Points: 
  • The internal neuromodulation segment accounted for the largest share of the Neuromodulation Market.
  • Based on technology, the neuromodulation is segmented into internal neuromodulation and external neuromodulation.
  • The internal neuromodulation segment accounted for the largest share of the market in 2019.
  • The transcutaneous electrical nerve stimulation segment accounted for the largest share of the External Neuromodulation Market in 2019.